Glenmark Pharmaceuticals Ltd.

Market Capital
₹24,120 Cr.
P/E
94.72
Share Price
₹ 849.1 -6.4 (-0.75%)

Glenmark Pharmaceuticals Ltd.

Quick View
₹ 849.1 -6.4 (-0.75%)
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Forensics
ROE
Asset Turnover is responsible for ROE increase over last 10 years
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Depreciation Effect
Company is depreciating a greater percentage of assets. This is contributing to a reduction in Net Profit
Pledge
Promoters have not pledged a significant portion of their holding
Working Capital
Working Capital of the company seems to be under control
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years but more due to rerating
Current vs Historic Valuation
Company is trading at a premium to 3yr historic valuations
Promoter Holding
Promoter has not sold any shares in the last 90 days
Debt
Company should not have issues servicing its debt
ROE
Latest
3.14%
3yr Average
9.08%
5yr Average
11.3%
Net Profit Margin
Latest
2.29%
3yr Average
6.27%
5yr Average
7.09%
ROCE
Latest
15.85%
3yr Average
17.22%
5yr Average
17.22%
Debt to Equity
Latest
0.46
3yr Average
0.51
5yr Average
0.62
Market Share
1.90% (as of Jul 22)
Anti - Diabetes - Market Share
15% (as of Mar 18)
Anti Dandruff Shampoo (Scalpe+) Market Share
locked Source
2.38% (as of Jul 22)
Anti-Infectives - Market Share
0.35% (as of Nov 21)
Antineo Plastic - Market Share
4.12% (as of Jul 22)
Cardiovascular - Market Share
8.80% (as of Nov 21)
Dermatology - Market Share
0.01% (as of Feb 21)
Endocrinology - Market Share
0.09% (as of Jul 22)
Gastro-Intestinal - Market Share
0.01% (as of Nov 21)
Gynecology - Market Share
0.12% (as of Nov 21)
Neurological - Market Share
1.40% (as of Nov 21)
Ophthalmology - Market Share
0.10% (as of Nov 21)
Pain - Market Share
2.10% (as of Dec 22)
Pharmaceutical Sector - Market Share
5.48% (as of Nov 21)
Respiratory - Market Share
0.19% (as of Nov 21)
Stomatological - Market Share
0.02% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Glenmark generics

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Glenmark Pharma (Branded generics)

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Number of ANDA's Filed in USA (Nos)
      Source
    • Number of ANDA's Approved By USFDA (Nos)
      Source
    • Domestic Sales Growth - YoY (%)
      Source
    • Management Compensation as a % of Sales (%)
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Glenmark Pharmaceuticals Ltd.
    View the discussion on ValuePickr
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline
    Sign Up for Free